Literature DB >> 14623771

Effect of peptidases on the ability of exogenous and endogenous neurokinins to produce neurokinin 1 receptor internalization in the rat spinal cord.

Juan Carlos G Marvizon1, Xueren Wang, Li-Jun Lao, Bingbing Song.   

Abstract

The ability of peptidases to restrict neurokinin 1 receptor (NK1R) activation by exogenously applied or endogenously released neurokinins was investigated by measuring NK1R internalization in rat spinal cord slices. Concentration-response curves for substance P and neurokinin A were obtained in the presence and absence of 10 microm thiorphan, an inhibitor of neutral endopeptidase (EC 3.4.24.11), plus 10 microm captopril, an inhibitor of dipeptidyl carboxypeptidase (EC 3.4.15.1). These inhibitors significantly decreased the EC50 of substance P to produce NK1R internalization from 32 to 9 nm, and the EC50 of neurokinin A from 170 to 60 nm. Substance P was significantly more potent than neurokinin A, both with and without these peptidase inhibitors. In the presence of peptidase inhibitors, neurokinin B was 10 times less potent than neurokinin A and 64 times less potent than substance P (EC50=573 nm). Several aminopeptidase inhibitors (actinonin, amastatin, bacitracin, bestatin and puromycin) failed to further increase the effect of thiorphan plus captopril on the NK1R internalization produced by 10 nm substance P. Electrical stimulation of the dorsal root produced NK1R internalization by releasing endogenous neurokinins. Thiorphan plus captopril increased NK1R internalization produced by 1 Hz stimulation, but not by 30 Hz stimulation. Therefore, NEN and DCP restrict NK1R activation by endogenous neurokinins when they are gradually released by low-frequency firing of primary afferents, but become saturated or inhibited when primary afferents fire at a high frequency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623771      PMCID: PMC1574162          DOI: 10.1038/sj.bjp.0705578

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  61 in total

1.  Effect of peptidase inhibition on the pattern of intraspinally released immunoreactive substance P detected with antibody microprobes.

Authors:  A W Duggan; H G Schaible; P J Hope; C W Lang
Journal:  Brain Res       Date:  1992-05-08       Impact factor: 3.252

2.  Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.

Authors:  F Noble; S Turcaud; M C Fournié-Zaluski; B P Roques
Journal:  Eur J Pharmacol       Date:  1992-11-13       Impact factor: 4.432

3.  Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.

Authors:  F Noble; P Coric; M C Fournié-Zaluski; B P Roques
Journal:  Eur J Pharmacol       Date:  1992-11-13       Impact factor: 4.432

4.  Aminopeptidase P from rat brain. Purification and action on bioactive peptides.

Authors:  H T Harbeck; R Mentlein
Journal:  Eur J Biochem       Date:  1991-06-01

5.  Leucine aminopeptidase: bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis.

Authors:  S K Burley; P R David; W N Lipscomb
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

6.  Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.

Authors:  F Noble; J M Soleilhac; E Soroca-Lucas; S Turcaud; M C Fournie-Zaluski; B P Roques
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

7.  Phosphoramidon potentiates mammalian tachykinin-induced biting, licking and scratching behaviour in mice.

Authors:  T Sakurada; K Tan-No; T Yamada; S Sakurada; K Kisara
Journal:  Pharmacol Biochem Behav       Date:  1990-12       Impact factor: 3.533

8.  Gamma-aminobutyric acidB, but not gamma-aminobutyric acidA receptor activation, inhibits electrically evoked substance P-like immunoreactivity release from the rat spinal cord in vitro.

Authors:  M Malcangio; N G Bowery
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

9.  Blind patch-clamp recordings from substantia gelatinosa neurons in adult rat spinal cord slices: pharmacological properties of synaptic currents.

Authors:  M Yoshimura; S Nishi
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

10.  Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme.

Authors:  S Tieku; N M Hooper
Journal:  Biochem Pharmacol       Date:  1992-11-03       Impact factor: 5.858

View more
  13 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

2.  Src family kinases mediate the inhibition of substance P release in the rat spinal cord by μ-opioid receptors and GABA(B) receptors, but not α2 adrenergic receptors.

Authors:  Guohua Zhang; Wenling Chen; Juan Carlos G Marvizón
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

3.  N-methyl-D-aspartate receptors and large conductance calcium-sensitive potassium channels inhibit the release of opioid peptides that induce mu-opioid receptor internalization in the rat spinal cord.

Authors:  B Song; J C G Marvizón
Journal:  Neuroscience       Date:  2005-10-03       Impact factor: 3.590

4.  Mechanisms of μ-opioid receptor inhibition of NMDA receptor-induced substance P release in the rat spinal cord.

Authors:  Wenling Chen; Helena S Ennes; James A McRoberts; Juan Carlos Marvizón
Journal:  Neuropharmacology       Date:  2017-10-16       Impact factor: 5.250

5.  μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.

Authors:  W Chen; J A McRoberts; J C G Marvizón
Journal:  Neuroscience       Date:  2014-02-26       Impact factor: 3.590

6.  Neuropeptide Y release in the rat spinal cord measured with Y1 receptor internalization is increased after nerve injury.

Authors:  Juan Carlos Marvizon; Wenling Chen; Weisi Fu; Bradley K Taylor
Journal:  Neuropharmacology       Date:  2019-08-02       Impact factor: 5.250

7.  Acute inflammation induces segmental, bilateral, supraspinally mediated opioid release in the rat spinal cord, as measured by mu-opioid receptor internalization.

Authors:  W Chen; J C G Marvizón
Journal:  Neuroscience       Date:  2009-03-17       Impact factor: 3.590

8.  NMDA receptors in primary afferents require phosphorylation by Src family kinases to induce substance P release in the rat spinal cord.

Authors:  W Chen; G Zhang; J C G Marvizón
Journal:  Neuroscience       Date:  2010-01-13       Impact factor: 3.590

9.  Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization.

Authors:  Guohua Zhang; Wenling Chen; Lijun Lao; Juan Carlos G Marvizón
Journal:  Eur J Neurosci       Date:  2010-01-13       Impact factor: 3.386

10.  Substance P release and neurokinin 1 receptor activation in the rat spinal cord increase with the firing frequency of C-fibers.

Authors:  D Adelson; L Lao; G Zhang; W Kim; J C G Marvizón
Journal:  Neuroscience       Date:  2009-03-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.